COVID Vaccine Roll Out Plan – Here’s What You Should Know
We are on the cusps of the vaccine being distributed for the coronavirus.
The progression of how quickly this vaccine has come about it truly remarkable and I don’t think that anyone other than President Trump could have made this happen so quickly.
I don’t know how you personally feel about vaccines in general, or this vaccine specifically, but it’s at least worth discussing what’s about to occur with this vaccine.
Next month, we should start seeing the vaccine begin to be administered. So who is going to get it first?
Well, upon rollout, the first doses are going to go out to those who are deemed as high-risk. That would include people with cancer, diabetes, blood disorders, lung problems, kidney or liver disease, moderate to severe asthma, and obesity.
Next, they’ll begin to be become more available for those who are over the age of 65 years old with some underlying conditions, people in prison or jail, people who work in a high risk environment such as school teachers and daycare workers.
Following that round of vaccines, younger adults will get them and especially those in certain industries that deal with more people such as banks, hotels, colleges, and factories.
Then the last round will include everyone else.
As The Daily Wire previously reported, the first two vaccines to show promise “still have to go through final testing and get approval by the Food and Drug Administration (FDA), at which time the CDC panel study clinical trial data to see side effects on people of various ages, ethnicities and health.”
“After that, the CDC will decide who gets priority for the vaccine and state health services are expected to follow the CDC’s guidance,” the outlet continued.
“The analysis evaluated 95 confirmed Covid-19 infections among the trial’s 30,000 participants,” CNBC reported. “Moderna, which developed its vaccine in collaboration with the National Institute of Allergy and Infectious Diseases, said 90 cases of Covid-19 were observed in the placebo group versus 5 cases observed in the group that received its two-dose vaccine. That resulted in an estimated vaccine efficacy of 94.5%.”
About 20 million doses of the vaccine should be ready by the end of the year.